Curran Terrie sold $956K of ARQT

Curran Terrie sold 38,200 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.03 ($0.96M total) across 2 trades on 2026-08-27.

Original reporting
SEC EDGAR · Curran Terrie
Published Aug 28, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
medium confidence
Mentioned
$ARQT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The transaction is a primary disclosure but small in scale, offering limited trading insight.

02

Market read

Minor insider sale with low materiality; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data releases or financing needs that prompted the director to liquidate shares.

Relevance 5/10Novelty 5/10Timing: post-market today

Background

Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$ARQTNeutralMedium confidence
Context

Director Curran Terrie sold 38,200 shares for $956K on 2026-08-27, reducing his holding to 23,526 shares.

Expected impact

Minimal short-term price effect; may cause slight downward pressure if aggregated with other insider sales.

Evidence & confidence

A $956K sale by a director is a routine liquidity event; the size is not material for a mid‑cap biotech, so market reaction is likely muted.

Market effects

No broader sector impact; biotech peers unlikely to be affected.

Limited to US biotech market, negligible.

None

Counterpoint

The sale could be interpreted as a red flag if multiple insiders sell around the same time.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies, ticker ARQT.

  • Curran Terrie

    Director of Arcutis Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.